Hello everyone, so my name is Yaky and I am the CEO of Pluri Bio. I'll keep it short and sweet, talking about how we're using cells in order to promote well-being, aging, and longevity. And I did tell it to Eyal privately during lunch, I promised for you making sure that this conference will happen no matter the situation is. He actually is, and you have my full appreciation for that. So thank you, and for all the great work that you are doing all over the years.
So well guys, that's the problem, that's the source of the problem that we are fighting today in our conference. Why are we dying? And I don't know if you made it by purpose, Eyal, surprisingly that was actually the parsha, that was the chapter of this week in the Bible that we read every year, every Shabbat. The chapter, it's actually the beginning. And guys, that's probably according to the Bible the reason that we are dying, and this is the reason that we are aging. So that's the source, and everything that we are doing since then is to try to find solutions to what Eve or Chava was doing, eating from the fruit. And we are somehow trying to see how we can keep ourselves alive even though this is how we started.
But talking about Eve and women, we are the placenta. Guys, I love placentas. I'm amazed by cells, and we speak about it for years. But in my opinion, it just makes sense to take young, potent cells that are coming after full-term delivery and using them in order to regenerate and to heal our bodies. Generally, cells in my opinion hold a huge promise to many of humanity's challenges that we are facing, because everything on this planet that is living is built from cells. I like to call cells the building blocks of life. We are built from cells, our fruit trees, the tiniest bacteria. And my goal in life, and this is what my company is doing, is trying to create products out of cells for therapeutic use. I believe in placenta. I believe it's quite an amazing organ, very interesting from an immunological point of view. And we can use young, donated placenta in order to create therapeutics.
In Pluri, we invested quite a lot in building a technology that can allow us to manufacture cells on scale. And we invested heavily, over $300 million. That's what allows us today to have this bioreactor system that we can expand cells in a dramatic manner. Today we use it across different industries, but these systems are so effective that from a single placenta today we know to manufacture over 20,000 doses. So we can treat over 20,000 patients from a single placenta.
We do work with several types of different cells that are deriving from placenta. And what we know is that once we are administering these cells into the patient's body, the cells start to interact with the patient's body. They are able to get signals from the body and to respond to it by secreting a variety of different proteins, cytokines, exosomes, which eventually leads to regeneration and healing. The advantage of using cells is it's a living organism. And for me, it just makes sense to treat a body which is built from cells with cells. I always say placenta cells are native speakers; they understand the language of the body, so they can read the signals and respond to it. And this is what we are trying to do in all the medicine over all the years, and this is what Pluri is expert about.
We work for 15 years using one type of cells, the adherent stromal cells derived from placenta. We have several products. We use it quite successfully, treated hundreds of patients for many conditions: hematological deficiencies, muscle regeneration, and more and more and more. Today we are also using a different type, which is a non-conventional T-cell derived from placenta, in immunotherapy fashion in order to combat cancer. And I like the title of the presentation: if you like to stay alive, make sure that you're not going to get cancer. It's true, but if you're getting cancer, so we need to treat it somehow. So we are all about placenta, it's about different cells, and about using these cells for therapeutics.
But that's a problem: that we use cells for therapeutics and not for well-being, healthy human beings. And this is the big shift that all of us want to do at a certain point: how we can do prevention, and if we are as human beings which are in good health are eligible for cell therapy treatment in order to keep and to preserve our well-being. We are talking, I'm for years, over a decade, I do try to understand the aging phenomena. And we all know it very well: complex conditions that are coming from different organs, from ischemia, muscle wasting, the age of our immune system, the fact that our cells get into a senescence mode, inflammation. It's a real complicated and comprehensive solution that we need to overcome.
What is interesting is that if I'm going to slice and dice it per indication, today I have good clinical evidence that we can use these placenta cells to treat any of these conditions separately. Why separately? Because today, unfortunately, I am treating patients. I hope that the day will come that we're going to treat healthy human beings in order to make sure that we're going to keep our well-being, aging, and longevity. And let me give you a few examples to understand what we can do with placenta cells.
One of the most important parts, and we all know, is the muscle wasting. We can easily see people by their skeletal muscle fitness and volume. In Pluri, we did several studies with the Charité of Berlin, which is our European partner. But in a quite large Phase 3 study, we were able to demonstrate that if we inject these placenta cells into muscle, we can increase the muscle volume and we can increase the muscle force in a statistically significant manner. This is some finding from the Phase 1 and Phase 2, but we also repeated and published the Phase 3 study that we measured. So once the cells are injected into the muscle, they interact, they secrete a lot of factors that allow the muscle a much better and faster regeneration, and we get a stronger and a larger muscle. Well, that's great for patients after hip fracture, but why not for patients or healthy people that are just aging and from 25, 50, losing the muscle mass? I think we should do it.
Ischemia. We know that ischemic condition is a part of the aging. We see ischemia in the leg, in our hearts, in all our arteries and blood vessels. We have good evidence that if we are treating patients with severe ischemia, in this case again end-stage patients with CLI, patients that are in risk of amputation, we are able to save the legs because our cells secrete factors that allow the body to start and to create additional or new blood vessels by doing angiogenesis, the natural angiogenesis that the body knows how to do. So it's all about it: our body knows how to regenerate. We are losing it at a certain time, or it's slowing down at a certain point of time when we are aging. And I believe that it's as simple as that: take young, fresh, potent cells, give them to an aged human being, and you can see some interesting stuff going on.
I guess most of you know about a lot of studies that were done on mice saying that if you take young blood and inject it to elderly mice, you can see the outcome. So our cells, and we have different types of cells that we use for different disorders. Pluri always works in collaboration. This is a great collaboration that can give us also some indication for hematological deficiency. We know that the age of the immune system is a critical part of how well we are aging. We have quite an interesting program today that we are doing with the Department of Defense and DTRA using our cells to treat hematological deficiencies after exposure to very high levels of nuclear radiation. And again, I'm treating patients, I want to treat healthy human beings, but we know that our cells can be very impactful over there.
And for the cancer, we are developing now, it's relatively early stage but quite promising, an immunotherapy model based on placenta cells in an allogeneic fashion. So we hope and believe that we can overcome the shortage of the supply of immunotherapy, which we all know that it's effective but still very costly and with quite limited access to patients. And that's something that I hope that next year we will be able to report on more success on that. But working with placenta cells, expanding them, using the immunotherapy, that's something which can be a very, very powerful component.
It's not relating to aging, but just to tell you what I have in my mind: I believe in cells. Cells are important for health, but they're important for many, many more different industries. And I urge anyone of you that have a good idea to contact me, because in Pluri we are actually building a collaborative network of companies. We are building different companies around us that we are spinning them out, always using the same platform that we have. And in the last two years, I did things that I never thought I'm going to do, like building a company with Nuclia for cultivated meat using our technology, which was for expansion of placenta cells but now for meat. We're now partnering also around ACTC for several applications. Always the same thing: if you have a great idea that you need the most amazing manufacturing technology of cells in the world, we are building a series of companies around us. And the company that I'm very, I'm looking forward to see it very soon, is around aging and longevity that will devote all its energy towards building the solutions for aging and longevity. It needs to be a separate one from the pharma because it's not treating patients.
And I started with the Bible and I will end with the Bible. One of the promises, or one thing that we know that we also read this week, and I always say: the first man, Adam, he lived to 930 years. So who knows, maybe this is our biological potential. We need to do a lot of good work. I can say that I hope that next year we're going to see significant progress in aging all over the world. I think that all of us did an okay work, but we can do more than that. And this is where we should look for it. The first man, Adam, 930 years. Here's the goal. Thank you.
